Panacea Biotec Ld Holds 42nd AGM on Sep 29, 2026, Voting Results by Oct 1
Panacea Biotec Limited held its 42nd AGM on September 29, 2026, via Video Conference. Key businesses included adopting FY26 financial statements and re-appointing directors. Voting results and the Scrutinizer’s Report are expected by October 1, 2026.
The AGM is a routine corporate event. While it involves important decisions like financial statement adoption and director re-appointments, the primary impact is on corporate governance and shareholder communication rather than immediate business operations or financial performance.
The announcement details the proceedings of the AGM, including the businesses transacted and the schedule for releasing voting results. No specific financial outcomes or significant new information were disclosed that would strongly influence sentiment.
Panacea Biotec Limited held its 42nd Annual General Meeting (AGM) on Tuesday, September 29, 2026, commencing at 11:30 A.M. through Video Conferencing (VC). The meeting was conducted in accordance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Due to the absence of Dr. Rajesh Jain, Chairman and Managing Director, Mr. Krishan Kumar Jalan, an Independent Director, was elected as the Chairman of the meeting. Mr. Ankesh Jain and Mr. Harshet Jain, Whole-time Directors, were also unable to attend.
The AGM included the consideration and adoption of Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. Additionally, the re-appointment of Mr. Ankesh Jain and Mr. Harshet Jain as retiring directors, the appointment of Mr. Rajinder Singh Manku as an independent director, and the ratification of remuneration for M/s Jain Sharma & Associates, Cost Auditors for the financial year 2026-27, were taken up for shareholder approval.
Shareholders raised queries regarding financial performance, vaccine development status, regulatory approvals, and future plans. The management assured that responses to these queries would be provided in due course. The voting results, along with the consolidated Scrutinizer’s Report, are scheduled to be declared by October 01, 2026, and will be published on the company's website and other relevant platforms. The meeting concluded at 12:12 P.M.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.